Clinicodemographic Profile of Metastatic Prostate Cancer Patients in a Tertiary Care Centre

Aggarwal N, Raja Anand, Raj Hemanth E an .

Abstract


Aim of the study: was to examine the clinical and

treatment features of patients presenting with metastatic

prostate cancer in our tertiary care centre. Material: Data

was collected retrospectively over a 5 year period from

tumor registry records. Results: Majority of patients were

symptomatic upfront with bone metastasis commonly at

presentation. Median PSA at presentation was 155.5 ng/

ml. Overall median time to progression was 10 months.

Site of metastasis, PSA value, Gleason grade and mode of

treatment were not adverse prognostic factors.

Conclusion: Clinical, pathological and treatment factors

did not predict a decreased time to progression. Hence,

molecular markers can be tried to predict survival

outcomes. No difference with respect to medical and

surgical castration and progression to CRPC.

 


Full Text:

PDF

References


http://nrcpindia.ORG/ALL_NRCP_REPORTS/

PBCR_REPORT_ 2012_2014/

Gronberg , H. Prostate Cancer Epidemiology. The Lancet

; 361 (9360): 859-864.

Bubendorf, L.; Schopfer, A.; Wagner, U.; Sauter, G.;

Moch, H.; Willi, N.; Gasser, T.C.; Mihatsch M. J. Metastatic

patterns of prostate cancer: An autopsy study of 1,489

patients. hum. patrol, 2000,31,578-583.

Weight CJ, Klein EA, Jones JS. Androgen deprivation falls

as orchidectomy rated rise after changes in reimbursement

in US medicare population. Cancer. 2008; 112 (10): 2106-7.

Chon J K , Jacobs S C, Naslund M J. The cost of medical

versus surgical hormonal therapy for metastatic prostate

cancer. The journal of Urology, 2000,164 (3) : 735-737.

Botto H, Roupret M, Mathieu F, Richard F. Multicentre

randomized trial comparing triptorelin medical castration

versus surgical castration in the treatment of locally

advanced or metastatic prostate cancer. Progress en

Urologie, 2007, 17(2):235-239.

Denis L, Murphy GP. overview of prostate phase III trials

on combined androgen treatment in patients with metastatic

prostate cancer. Cancer 1993; 72:3888-3895.

Gandaglia G et al. Impact of the site of metastasis on

survival in patients with metastatic prostate cancer. Eur Urol

, http://dx.doi.org/10.1016/j.euroro.2014.07.020.

Ross RW, Xie W, Regan MM, Pomerantz M, Nakabayashi

M, Daskivich TJ, Sartor O, Taplin ME, Kantoff PW, Oh WK.

Efficacy of androgen deprivation therapy (ADT) in patients

with advanced prostate cancer: association between Gleason

score, prostate-specific antigen level, and prior ADT

exposure with duration of ADT effect. Cancer. 2008;112

(6):1247–1253.

Morote J, Esquena S, Abascal JM, Trilla E, Cecchini L,

Raventos CX, Orsola A, Planas J, Catalan R, Reventos J.

Usefulness of prostate-specific antigen nadir as predictor of

androgen-indepen- dent progression of metastatic prostate

cancer. Int J Biol Markers. 2005;20(4):209–216.


Refbacks

  • There are currently no refbacks.


Creative Commons License
This work is licensed under a Creative Commons Attribution-NoDerivatives 4.0 International License.

An Initiative of The Tamil Nadu Dr MGR Medical University